FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/03/023789 [Registered on: 05/03/2020] Trial Registered Prospectively
Last Modified On: 02/08/2021
Post Graduate Thesis  No 
Type of Trial  PMS 
Type of Study   Drug
Behavioral 
Study Design  Non-randomized, Active Controlled Trial 
Public Title of Study   Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety & Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomnia in Actual Field Conditions Of Use. 
Scientific Title of Study   Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety & Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomnia in Actual Field Conditions Of Use. 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Nimesh Patel 
Designation  M.D. General Medicine 
Affiliation  Sanjeevani Heart & Medical Hosptial 
Address  Sanjeevani Complex,near Devasya Clinic, Opposite Mehsana Society, Vadaj road

Ahmadabad
GUJARAT
380013
India 
Phone  27641742  
Fax    
Email  dr_nimesh_patel@yahoo.co.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Nimesh Patel 
Designation  M.D. General Medicine 
Affiliation  Sanjeevani Heart & Medical Hosptial 
Address  Sanjeevani Complex,near Devasya Clinic, Opposite Mehsana Society, Vadaj road

Ahmadabad
GUJARAT
380013
India 
Phone  27641742  
Fax    
Email  dr_nimesh_patel@yahoo.co.in  
 
Details of Contact Person
Public Query
 
Name  Dr Nimesh Patel 
Designation  M.D. General Medicine 
Affiliation  Sanjeevani Heart & Medical Hosptial 
Address  Sanjeevani Complex,near Devasya Clinic, Opposite Mehsana Society, Vadaj road

Ahmadabad
GUJARAT
380013
India 
Phone  27641742  
Fax    
Email  dr_nimesh_patel@yahoo.co.in  
 
Source of Monetary or Material Support  
AN Pharmacia Laboratories Pvt ltd 
 
Primary Sponsor  
Name  AN Pharmacia Laboratories Pvt ltd 
Address  21-23, Industrial Area, Mehatpur, dist – Una, Himachal Pradesh  
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Nimesh Patel  Sanjeevani Heart and Medical Hospital  Sanjeevani complex, Opposite Mehsana Society, Nava Vadaj Road, Ahmedabad
Ahmadabad
GUJARAT 
7927641742

dr_nimesh_patel@yahoo.co.in 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 4  
Name of Committee  Approval Status 
Ashirwad Ethics Committee  Approved 
Ethics committe Sanjeevani Hospital  Approved 
Institutional Ethics Committee, NIMS University Rajasthan, Jaipur  Approved 
Shri Durgamba Independent Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: F411||Generalized anxiety disorder,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  FDC of Diazepam and Propranolol  Treatment of Chronic anxiety & Insomnia Frequency: Twice a day Dose: Combination of Diazepam 2.5mg and Propanol Hydrochloride 20mg Route of administration: Oral 
Comparator Agent  NOT APPLICABLE  NOT APPLICABLE 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1. Both Male and Female patient.
2. Ages: > 18 years and < 65 years.
3. Patients with Chronic Anxiety and Insomnia.
4. Confirmed diagnosis of primary insomnia (as defined by
the Diagnostic and Statistical Manual for Mental
Disorders-IV [DSM-IV-TR]) present at the time of
evaluation for at least 3 months
5. Baseline Hamilton Rating Scale for Anxiety (HAMA)
scores ≥18
6. Patient with history of primary insomnia
7. Women of child bearing age willing to take contraceptive
measure to prevent pregnancy during the study
8. Patients willing to give written informed consent 
 
ExclusionCriteria 
Details  1. History of hypersensitivity to the study drugs
2. Chronic heart failure, respiratory failure or chronic liver and renal failure.
3. Patient with active cancer
4. Female who is pregnant, planning a pregnancy (during the course of the study) or nursing a child
5. Certain medications that may interfere with the study medication and worsen the patient condition (these will be identified by the study Investigator).
6. Patients with a history of chronic hepatitis B or C infection, HIV infection.
7. Clinically significant disorder that may unsuitable for study participation. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment    
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Assessment based on HAMA scale, Clinician Global Impression (CGI) and Patient Global Impression (PGI) scales  14 days 
 
Secondary Outcome  
Outcome  TimePoints 
Evaluate efficacy of this FDC in treatment of Chronic Anxiety and Insomnia.  14 days 
 
Target Sample Size   Total Sample Size="200"
Sample Size from India="200" 
Final Enrollment numbers achieved (Total)= "0"
Final Enrollment numbers achieved (India)="200" 
Phase of Trial   Post Marketing Surveillance 
Date of First Enrollment (India)   09/03/2020 
Date of Study Completion (India) 03/04/2021 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="2"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  
Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety
&amp; Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety &amp; Insomnia in Actual
Field Conditions Of Use.

Primary Objective:

The primary objective of this PMS trial is to find out safety & tolerability of the product in patient with Chronic Anxiety and Insomnia”

Secondary Objective:

The secondary objective of this PMS trial is to find out efficacy of the product by clinician global assessment.
 
Close